Full-Length RNA-Seq Tech Note

Full-Length RNA-Seq: A Novel Method to Assess Sequence Integrity for RNA Therapeutics

The use of RNA therapeutics as a gene therapy approach continues to expand due to the ability to target specific genes and introduce defined RNA transcripts. To develop these therapies, strict quality control is required to ensure the integrity of poly(A) tails, which are essential for mRNA stability and translation efficiency. However, current assays for measuring poly(A) tails present important limitations, including inaccurate length detection, limited resolution of mixed populations, and the introduction of technical artifacts.

Using NGS-based PacBio® Small-Molecule, Real-Time (SMRT®) sequencing, GENEWIZ from Azenta Life Sciences has developed a high-throughput, full-length RNA sequencing (RNA-Seq) workflow that enables sequencing of manufactured RNA products while preserving the full-length poly(A) tail. In this tech note, explore the science behind this novel full-length RNA-Seq assay and learn how it provides an optimal quality control approach for the development of mRNA-based vaccines and RNA therapeutics.

What You'll Learn

• Key challenges associated with sequencing full-length RNA molecules using traditional analytical approaches
• How the full-length RNA-Seq workflow from GENEWIZ enables accurate sequencing of manufactured RNA products while preserving poly(A) tail integrity
• Results from internal validation studies confirming quantification accuracy, reproducibility, and consistency of the full-length RNA-Seq assay